We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
RVMD Stock Rallies 41% on Positive Phase III Pancreatic Cancer Data
Read MoreHide Full Article
Key Takeaways
Revolution Medicines shares surged 41% after positive phase III daraxonrasib data in PDAC patients.
RVMD's drug showed a median OS of 13.2 months vs. 6.7 months for chemotherapy in the overall study population.
Revolution Medicines plans global filings, with an FDA submission under the Priority Voucher program.
Shares of Revolution Medicines (RVMD - Free Report) surged 41% after the company announced that its pivotal phase III RASolute 302 study evaluating daraxonrasib, its lead pipeline candidate in previously treated patients with metastatic pancreatic ductal adenocarcinoma (PDAC), met all primary and key secondary endpoints.
Key Details of RVMD’s Phase III RASolute 302 Study for PDAC
RASolute 302 is a global, randomized phase III registrational study evaluating the safety and efficacy of daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, as monotherapy in patients with metastatic PDAC. The study enrolled a broad patient population, including those with diverse RAS mutations, particularly G12 variants, as well as those without identifiable RAS mutations. Participants were randomized to receive either 300 mg of oral daraxonrasib once daily or standard-of-care cytotoxic chemotherapy delivered intravenously.
Year to date, shares of RVMD have risen 71.1% compared with the industry’s 0.6% growth.
Image Source: Zacks Investment Research
The primary endpoints of the study included progression-free survival (PFS) and overall survival (OS) in patients with RAS G12-mutant tumors, while secondary endpoints evaluated these outcomes in the overall study population, along with response rates, duration of response and patient-reported quality of life.
Daraxonrasib demonstrated statistically significant and clinically meaningful improvements in both PFS and OS compared with standard intravenous cytotoxic chemotherapy. In the overall study population, patients receiving daraxonrasib achieved a median OS of 13.2 months versus 6.7 months for chemotherapy. The therapy was generally well tolerated, with a manageable safety profile and no new safety signals identified.
Based on these data, Revolution Medicines plans to advance regulatory submissions globally, including a new drug application to the FDA under the Commissioner’s National Priority Voucher program.
More on RVMD’s Daraxonrasib
Daraxonrasib is designed to target a broad spectrum of RAS-driven cancers, including PDAC, non-small cell lung cancer (NSCLC) and colorectal cancer and is currently being studied across four global late-stage studies, three in PDAC (RASolute 302, RASolute-303 and RASolute 304) and one in NSCLC (RASolve 301), positioning it as a potentially first-in-class therapy in a setting with high unmet medical need.
While the RASolute 302 study is assessing the candidate in patients with second-line metastatic PDAC, the RASolute 303 study is evaluating its efficacy in the first-line metastatic setting of the disease. Revolution Medicines is also evaluating daraxonrasib in the RASolute 304 study as an adjuvant therapy for patients with resectable PDAC.
Revolution Medicines is conducting the RASolve 301 study in patients with locally advanced or metastatic RAS-mutated NSCLC. The company is also on track to start a fifth late-stage study on daraxonrasib in the first-line NSCLC setting in 2026.
The FDA previously granted daraxonrasib Breakthrough Therapy and Orphan Drug Designations for previously treated metastatic PDAC with G12 mutations.
Revolution Medicines’ Zacks Rank & Stocks to Consider
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.55 to $2.87. Over the same period, EPS estimates for 2027 have surged from $2.85 to $3.25. CPRX shares have gained 8.6% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have risen from $2.89 to $3.08. Over the same period, EPS estimates for 2027 have surged from $3.22 to $3.41. INDV shares have lost 11.9% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 74.53%.
Over the past 60 days, estimates for ANI Pharmaceuticals’ 2026 earnings per share have increased from $8.22 to $8.99. Over the same period, EPS estimates for 2027 have risen from $9.90 to $10.10. Year to date, shares of ANIP have declined 0.8%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, with the average surprise being 22.21%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
RVMD Stock Rallies 41% on Positive Phase III Pancreatic Cancer Data
Key Takeaways
Shares of Revolution Medicines (RVMD - Free Report) surged 41% after the company announced that its pivotal phase III RASolute 302 study evaluating daraxonrasib, its lead pipeline candidate in previously treated patients with metastatic pancreatic ductal adenocarcinoma (PDAC), met all primary and key secondary endpoints.
Key Details of RVMD’s Phase III RASolute 302 Study for PDAC
RASolute 302 is a global, randomized phase III registrational study evaluating the safety and efficacy of daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, as monotherapy in patients with metastatic PDAC. The study enrolled a broad patient population, including those with diverse RAS mutations, particularly G12 variants, as well as those without identifiable RAS mutations. Participants were randomized to receive either 300 mg of oral daraxonrasib once daily or standard-of-care cytotoxic chemotherapy delivered intravenously.
Year to date, shares of RVMD have risen 71.1% compared with the industry’s 0.6% growth.
Image Source: Zacks Investment Research
The primary endpoints of the study included progression-free survival (PFS) and overall survival (OS) in patients with RAS G12-mutant tumors, while secondary endpoints evaluated these outcomes in the overall study population, along with response rates, duration of response and patient-reported quality of life.
Daraxonrasib demonstrated statistically significant and clinically meaningful improvements in both PFS and OS compared with standard intravenous cytotoxic chemotherapy. In the overall study population, patients receiving daraxonrasib achieved a median OS of 13.2 months versus 6.7 months for chemotherapy. The therapy was generally well tolerated, with a manageable safety profile and no new safety signals identified.
Based on these data, Revolution Medicines plans to advance regulatory submissions globally, including a new drug application to the FDA under the Commissioner’s National Priority Voucher program.
More on RVMD’s Daraxonrasib
Daraxonrasib is designed to target a broad spectrum of RAS-driven cancers, including PDAC, non-small cell lung cancer (NSCLC) and colorectal cancer and is currently being studied across four global late-stage studies, three in PDAC (RASolute 302, RASolute-303 and RASolute 304) and one in NSCLC (RASolve 301), positioning it as a potentially first-in-class therapy in a setting with high unmet medical need.
While the RASolute 302 study is assessing the candidate in patients with second-line metastatic PDAC, the RASolute 303 study is evaluating its efficacy in the first-line metastatic setting of the disease. Revolution Medicines is also evaluating daraxonrasib in the RASolute 304 study as an adjuvant therapy for patients with resectable PDAC.
Revolution Medicines is conducting the RASolve 301 study in patients with locally advanced or metastatic RAS-mutated NSCLC. The company is also on track to start a fifth late-stage study on daraxonrasib in the first-line NSCLC setting in 2026.
The FDA previously granted daraxonrasib Breakthrough Therapy and Orphan Drug Designations for previously treated metastatic PDAC with G12 mutations.
Revolution Medicines’ Zacks Rank & Stocks to Consider
RVMD currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Catalyst Pharmaceuticals (CPRX - Free Report) and Indivior Pharmaceuticals (INDV - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy), and ANI Pharmaceuticals (ANIP - Free Report) , which carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.55 to $2.87. Over the same period, EPS estimates for 2027 have surged from $2.85 to $3.25. CPRX shares have gained 8.6% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have risen from $2.89 to $3.08. Over the same period, EPS estimates for 2027 have surged from $3.22 to $3.41. INDV shares have lost 11.9% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 74.53%.
Over the past 60 days, estimates for ANI Pharmaceuticals’ 2026 earnings per share have increased from $8.22 to $8.99. Over the same period, EPS estimates for 2027 have risen from $9.90 to $10.10. Year to date, shares of ANIP have declined 0.8%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, with the average surprise being 22.21%.